IL138051A0 - Pharmaceutical formulation containing a hyaluronic acid-splitting enzyme of microbial origin - Google Patents

Pharmaceutical formulation containing a hyaluronic acid-splitting enzyme of microbial origin

Info

Publication number
IL138051A0
IL138051A0 IL13805199A IL13805199A IL138051A0 IL 138051 A0 IL138051 A0 IL 138051A0 IL 13805199 A IL13805199 A IL 13805199A IL 13805199 A IL13805199 A IL 13805199A IL 138051 A0 IL138051 A0 IL 138051A0
Authority
IL
Israel
Prior art keywords
hyaluronic acid
pharmaceutical formulation
formulation containing
microbial origin
splitting enzyme
Prior art date
Application number
IL13805199A
Original Assignee
Id Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998160541 external-priority patent/DE19860541A1/en
Priority claimed from DE1998160542 external-priority patent/DE19860542A1/en
Application filed by Id Pharma Gmbh filed Critical Id Pharma Gmbh
Publication of IL138051A0 publication Critical patent/IL138051A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001—Hyaluronate lyase (4.2.2.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13805199A 1998-12-23 1999-12-22 Pharmaceutical formulation containing a hyaluronic acid-splitting enzyme of microbial origin IL138051A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1998160541 DE19860541A1 (en) 1998-12-23 1998-12-23 Composition for the treatment of vascular disease comprises holozyme with hyaluronate lyase activity from microbial origin
DE1998160542 DE19860542A1 (en) 1998-12-23 1998-12-23 An enzyme fragment with hyaluronate lyase activity is derived from streptococci and used for medical applications
PCT/DE1999/004108 WO2000039290A2 (en) 1998-12-23 1999-12-22 Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid

Publications (1)

Publication Number Publication Date
IL138051A0 true IL138051A0 (en) 2001-10-31

Family

ID=26051101

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13805199A IL138051A0 (en) 1998-12-23 1999-12-22 Pharmaceutical formulation containing a hyaluronic acid-splitting enzyme of microbial origin

Country Status (10)

Country Link
EP (1) EP1056839A1 (en)
JP (1) JP2002533473A (en)
KR (1) KR20010041235A (en)
AU (1) AU3032400A (en)
CA (1) CA2318356A1 (en)
DE (1) DE19982882D2 (en)
HU (1) HUP0103660A2 (en)
IL (1) IL138051A0 (en)
PL (1) PL344745A1 (en)
WO (1) WO2000039290A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963538A1 (en) * 1999-12-22 2001-07-05 Univ Schiller Jena Use of an enzyme to improve tissue absorption of drugs
DE10103271A1 (en) * 2001-01-23 2002-07-25 Knoell Hans Forschung Ev Pharmaceutical formulation containing hyaluronatlyase, useful for softening of connective tissue in medical and cosmetic treatment, especially in shape correction
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
WO2004110479A1 (en) * 2003-05-27 2004-12-23 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Hyaluronate lyase-containing agent for treating acute myocardial infarction or symptoms thereof and for the treatment of postinfarction myocarditis and myocardial ischaemia
DE102007031417A1 (en) 2007-07-04 2009-01-08 Friedrich-Schiller-Universität Jena Hyaluronate lyase with a histidine tag e.g. useful in pharmaceutical formulations and medical products
US20110130473A1 (en) 2007-11-13 2011-06-02 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
SG172064A1 (en) 2008-12-09 2011-07-28 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120298A (en) * 1966-07-11 1968-07-17 Biorex Laboratories Ltd Stabilised enzymes
US3708575A (en) * 1970-05-13 1973-01-02 Biorex Laboratories Ltd Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase
US3728223A (en) * 1971-10-08 1973-04-17 Amano Pharma Co Ltd Production of hyaluronidase from a strain of streptomyces
ATE245452T1 (en) * 1998-12-23 2003-08-15 Esparma Gmbh HYALURONATE LYASE AS A PENETRATION PROMOTER IN TOPICAL AGENTS

Also Published As

Publication number Publication date
KR20010041235A (en) 2001-05-15
WO2000039290A8 (en) 2000-10-19
AU3032400A (en) 2000-07-31
WO2000039290A3 (en) 2001-03-08
EP1056839A1 (en) 2000-12-06
JP2002533473A (en) 2002-10-08
PL344745A1 (en) 2001-11-19
CA2318356A1 (en) 2000-07-06
DE19982882D2 (en) 2001-10-04
WO2000039290A2 (en) 2000-07-06
HUP0103660A2 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
ZA987800B (en) Pharmaceutical composition of meloxicam
AU1875501A (en) System and method of distributing and returning products
AU9173698A (en) Microbial decontamination of food
AU6740298A (en) Pharmaceutical composition
AU5387898A (en) Pharmaceutical agents
AU5419500A (en) Bacteriophage rm 378 of a thermophilic host organism
AU1574900A (en) Pharmaceutical compositions containing insulin
AU5619400A (en) Statine-derived tetrapeptide inhibitors of beta-secretase
AU4328800A (en) Pharmaceutical formulation
AU8107998A (en) Pharmaceutical compositions
IL138051A0 (en) Pharmaceutical formulation containing a hyaluronic acid-splitting enzyme of microbial origin
AU7904998A (en) Pharmaceutical composition containing peptichemio
AU6949200A (en) Human hydrolytic enzymes
AU9343098A (en) Pharmaceutical composition
HU9802716D0 (en) Pharmaceutical composition of analgesic activity
AU1930097A (en) Slow-release pharmaceutical formulations containing mizolastin
IL146408A0 (en) Diphosphate salt of a 4-substituted-9-deoxo-9a-homoerythromycin derivative and its pharmaceutical composition
HUP0201880A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
AU4543500A (en) Pharmaceutical compositions and uses
AU3839900A (en) Pharmaceutical formulation
AU1677100A (en) Localization of software products
AU1567301A (en) Tablets comprising micro-organisms and method for preparation of the tablets
AU5182099A (en) Pharmaceutical formulation
AU1388501A (en) Pharmaceutical formulation
AU3989100A (en) Pharmaceutical gel formulation